Pharmacists Can Play Key Roles in Improving Health Outcomes for At-Risk Seniors

McKnight’s Senior Living

The concept of clinical pharmacy has evolved from the passions of a handful of graduates with doctorate-level practice degrees in the early 1990s to an entirely new standard of care, with 100% of graduates with advanced degrees and direct patient care experience today.

Technology and robotic automation have assisted in transitioning pharmacy practice beyond managing prescriptions to also directly managing patients and residents. Pharmacists have three evolving roles as a result of the drive toward value-based care.

In-home medication care specialists

Medication reconciliation perhaps is the most daunting task of the care transitions process. Over the course of a healthcare event, numerous clinicians, including hospitalists and specialists, often unfamiliar with the patient / resident, prescribe medications. These medications most often are based on facility formularies that may or may not align with what the patient or resident was taking before the episode or event. Pharmacists as in-home specialists (regardless of where a person’s “home” is) have proven to be more effective than other healthcare professionals in reconciling all medication lists into one comprehensive plan.

Pharmacists can help by:

  • Discussing with the patient or resident the medication profile in its totality, to increase knowledge and thus concordance;
  • Conducting a thorough medication safety review that considers all prescribed medications and over-the-counter drugs;
  • Assisting with de-prescribing and optimizing administration times;
  • Making recommendations to prescribers for alternatives to reduce the medication burden;
  • Identifying monitoring parameters to help avoid medication-related problems;
  • Clearly mapping out for patients and residents which medications to take, why and how to take them to avoid interactions;

In-home measures can drastically reduce the 30-day readmission rates.

Precision-prescribing “quarterbacks”

The formulary medication selection process often is based on market share/rebate incentives. Patients and residents often can be affected by business-focused contracts that result in reduced medication selection. So they may be prescribed medications that are not optimally co-administered — especially because obtaining nonformulary agents can result in delays in medication access and high co-payments.

Pharmacists can assist in the medication selection process (before dispensing occurs), helping physicians and facility medical directors find alternatives to medications that might cause drug-drug interactions or drug-drug-gene interactions. And, with pharmacogenomic data, prescribing becomes even more precise. Further, pharmacists can help avoid unintentional overdose and competitive inhibition drug interactions by providing guidance about medication administration times.

Pharmacists, who are medication experts, can help facilitate the prescribing process, especially when care coordination is lacking among providers. Involving pharmacists may even help drive the paradigm shift from formulary- and rebate-based prescribing toward a system that prioritizes medication outcomes.

Managers of medication benefits

The Program for All-Inclusive Care for the Elderly for Medicare / Medicaid dual-eligible beneficiaries is a prime example of value-based care that demonstrates how aligning incentives can eliminate the “silo effect” of Medicare Part D, which often is a cost-driver for Medicare Part A and B.

In many PACE organizations, pharmacists are able to proactively and prospectively collaborate with PACE and specialist prescribers to help optimize medication-related outcomes. In this high-risk population, pharmacists can identify whether a newly prescribed medication regimen increases a person’s risk for preventable adverse drug events. With the pharmacist in a real-time role, utilization, drug expenditures and total costs of care have been demonstrated to decrease and stabilize.

The science of “de-prescribing” is boldly confronting the problem of overprescribing. Pharmacists can advocate for both patients / residents and their insurers by optimizing regimens. This means ensuring the fewest medications required to manage chronic conditions while preserving their annual and lifetime medication benefits. Regardless of a medication’s cost, if it is the wrong medication for the patient or resident, then we’ve paid too much for it.

A systematic, prospective and personalized approach to the prescribing process can provide savings while improving clinical and economic outcomes, including patient / resident and provider satisfaction.

Overall, as value-based care moves from fee-for-service to fee-for-value, the pharmacist’s role will continue to evolve into one of responsibility for medication outcomes, as well as for the accuracy and timeliness of access.

Orsula Knowlton, PharmD, MBA, co-founded Tabula Rasa HealthCare with Calvin H. Knowlton, Ph.D. She is president and chief marketing/new business development officer. TRHC, based in Moorestown NJ , offers a suite of cloud-based software solutions to help healthcare organizations, prescribers and pharmacists better manage the medication-related needs of those in their care.

McKnight’s Senior Living welcomes marketplace columns on subjects of value to the industry. Please see our submission guidelines for more information.

Tabula Rasa HealthCare Named Best Performing IPO Among Top 50 Digital Health Companies in 2017

MOORESTOWN, N.J., Dec. 12, 2017 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare, Inc. (“TRHC”) (TRHC), a healthcare technology company advancing the field of medication safety, was named by Rock Health as the best performing IPO among digital health companies in 2017.

The Rock Health announcement released December 4 stated: “Tabula Rasa HealthCare provides at-risk healthcare organizations technology and services to optimize medication regimens with the goal of reducing hospitalizations, lowering costs, and mitigating risk. Tabula Rasa stock is up 140% based on YTD growth, which is the largest percent increase among public digital health companies in 2017.”

“It has been a tremendous year for TRHC in many respects,” said Chairman and CEO Calvin H. Knowlton, PhD. “Our stock has done well, indicating investors’ confidence in the company, its people, and its services. We have gained additional partners and expertise with the acquisition of Medication Therapy Management company SinfoníaRx. We also have been busy creating and deploying significant disruptive innovations, such as our recently released “Medication Risk Score”, a quick and easy way to assess which patients are at highest risk for adverse drug events (ADEs) and require medication management attention. We are pleased that these efforts have been recognized by Rock Health and their collaborators.”

Each year, Rock Health, Fenwick & West, Goldman Sachs, and Square 1 Bank award individuals and organizations for their contribution to the digital health community and healthcare ecosystem as a whole. Honorees are celebrated for their outstanding work at a dinner ceremony to be held January 7, 2018 in San Francisco during the JP Morgan conference.

About Tabula Rasa HealthCare, Inc.

Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payors, providers and other healthcare organizations.
For more information, please visit: www.TRHC.com.

Contact:
Media
Dianne Semingson
dsemingson@TRHC.com
T: 215-870-0829

Investors
Bob East or Asher Dewhurst
Westwicke Partners
443-213-0500
tabularasa@westwicke.com

Tabula Rasa HealthCare to Provide Care Transition Medication Management for Tandigm Health

MOORESTOWN, N.J. and WEST CONSHOHOCKEN, Pa., June 20, 2017 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare (TRHC), a healthcare technology company optimizing medication safety by deploying new Medication Risk Mitigation digital solutions and novel Medication Decision Support tools, and Tandigm Health, LLC, a value-based healthcare company supporting primary care physicians, announced today that Tandigm has engaged TRHC to assess the medication regimens of high-risk patients who were recently discharged from the hospital, to ensure that regimens are appropriate, effective, safe, taken as intended and have no drug interactions.

Through TRHC’s Care Transitions services, its geriatric certified clinical pharmacists will assess the medication regimen risk by using its Medication Risk Mitigation™ platform, MedWise Advisor®, to consider all medications used prior to a hospitalization and those prescribed upon discharge. Using TRHC’s advanced technology, TRHC pharmacists will work with Tandigm physicians and their patients to streamline and individualize medication regimens.   Outcomes expected to be realized from this initiative include reductions in adverse drug events (ADEs) and decreases in hospital readmission.

“At Tandigm Health, it all starts with healthcare quality,” said Tandigm Chief Medical Officer, Kenneth Goldblum, MD, FACP. “By prioritizing medication safety and effectiveness, we can help our physicians provide the best possible care to their patients as they transfer from a hospital or rehabiltation facilitiy to their homes. We believe TRHC’s unique medication risk mitigation platform and pharmacist follow-up with each patient will help us achieve this goal, and ultimately, reduce readmissions.”

TRHC offers the first prospective clinical solution to Medication Risk Mitigation, which is designed to increase patient safety by reducing the risk for multi-drug adverse drug events and personalizing a patient’s medication regimen. Its innovative technology platform is uniquely equipped to provide comprehensive medication risk management solutions to health plans and provider groups. TRHC’s services will further enhance Tandigm’s ability to provide network physicians with the tools and resources they need in order to deliver proactive, coordinated care.

“TRHC is delighted to partner with Tandigm Health to provide care transition medication risk management,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “Medication safety is our highest priority. We are pleased to deploy our medication risk mitigation platform, MedWiseAdvisor®, and clinical pharmacists services, on behalf of Tandigm’s physicians and their thousands of patients.”

The collaboration with Tandigm is an expansion of TRHC’s Care Transitions offering, which it launched earlier this year.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.TRHC.com.

About Tandigm Health

Tandigm Health is dedicated to enhancing the ability of primary care physicians to provide the finest possible care while lowering costs through a more coordinated, proactive model. By providing greater tools and resources to its network of more than 460 physicians, Tandigm puts primary care physicians back at the center of patient care. To learn more about Tandigm’s approach to value-based health care, visit www.tandigmhealth.com.

Tabula Rasa HealthCare Signs Three Year Agreement to Provide Medication Care Management for Multi-State PACE Sponsor

MOORESTOWN, N.J., Jan. 12, 2017 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare Corporation (TRHC), announces that a leading, multi-state, Program of All-Inclusive Care for the Elderly (PACE) provider has signed a three-year agreement for medication care management services.  The organization selected TRHC to help enhance quality, efficiency, and reduce total costs.

According to the Centers for Medicare and Medicaid Studies, PACE is a Medicare program for people over age 55 living with disabilities. The program provides community-based care and services to people who otherwise need nursing home care. PACE was created to provide flexibility to meet the health care needs of older Americans in order to help them continue living in their communities.  All of Medicare and Medicaid’s services are included for PACE enrollees, along with other services that are part of the PACE Interdisciplinary Team’s care plan.  Coverage for prescription drugs, primary care, transportation, home care, hospital visits, and nursing home stays, whenever necessary, are included for those enrolled in PACE.

The Agreement calls for TRHC to provide medication care management services, including comprehensive Medication Risk Mitigation®, and science-driven,  reminder-packaging pharmacy services for their PACE participants to help reduce the risk of adverse drug events while improving adherence.

“TRHC continues to advance the practice and science of medication risk mitigation through our personalized medicine approach,” said Chairman and CEO Calvin H. Knowlton, PhD. “We are pleased to have formalized the collaboration with this organization with the goal of optimizing outcomes for these frail-elderly individuals.”

About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Since 2011, TRHC has focused on optimizing outcomes for PACE and other healthcare organizations through its unique Medication Risk Mitigation software and Medication Decision Support and Adherence tools that personalize each participants medication regimen.  For more information, please visit: www.TRHC.com.

Tabula Rasa HealthCare Announces Third Quarter 2016 Operating Results

MOORESTOWN, N.J., Nov 09, 2016 (GLOBE NEWSWIRE via COMTEX) —

Tabula Rasa HealthCare, Inc. (“TRHC”) TRHC, +4.66% a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk, today announced its financial results for the third quarter ended September 30, 2016.

TRHC Chairman and CEO, Calvin H. Knowlton, Ph.D., commented, “I’m pleased with our performance during our first publically reported quarter. We continue to win new business within our core market, PACE (Program of All-Inclusive Care for the Elderly, a Medicare Advantage-type plan), as well as successfully expand our Medication Risk Mitigation platform into adjacent markets with other types of health plans, further proving its scalability.”

Dr. Knowlton continued, “There is significant runway ahead of us as we continue to develop and evolve our proprietary Medication Risk Mitigation platform and address larger patient populations with our goal of improving outcomes and lowering healthcare cost.”

Financial Performance for the Three Months Ended September 30, 2016

All comparisons, unless otherwise noted, are to the three months ended September 30, 2015.

  • Total revenue was $24.2 million, an increase of 35%. Total revenue included product revenue of $20.7 million, an increase of 35%, and service revenue of $3.4 million, an increase of 34%.
  • Gross margin was 29%, compared to 32%. The year over year decline is primarily related to a mix shift in client and business make-up, as well as to staffing increases associated with upcoming contracts.
  • Net loss was $142 thousand, compared to a net loss of $3.3 million. Third quarter 2016 included a $1.4 million expense related to the early extinguishment of debt.
  • Net loss per diluted share was $0.08, compared to a net loss per share of $3.21. The net loss per share calculations were based on a diluted share count of 10.3 million for the third quarter of 2016, compared to 4.4 million shares a year ago.
  • Non-GAAP Adjusted EBITDA was $3.3 million, compared to $2.4 million, an increase of 38% compared to a year ago. Adjusted EBITDA margin of 13.5% in the third quarter of 2016 compared favorably to 13.2% during the same period in 2015.
  • Non-GAAP Adjusted net income per diluted share was $0.06, compared to a net loss per share of $0.01.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. Non-GAAP results exclude change in fair value of warrant liability, loss on extinguishment of debt, change in fair value of acquisition-related contingent consideration (income) expense and stock-based compensation expense. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.

Business Outlook

Fourth Quarter 2016 Guidance: Revenue for TRHC’s fourth quarter 2016 is expected to be in the range of $25 million to $26 million. Net loss is expected to be in the range of $6 million to $7 million. Net loss projections include approximately $5 million of expense related to the extinguishment of debt associated with the early repayment of a credit facility in connection with TRHC’s initial public offering, as well as stock based compensation expense of approximately $3.5 million related to restricted stock grants and shares issued in connection with the initial public offering. Adjusted EBITDA is expected to be in the range of $3.5 million to $4.0 million.

Full Year 2016 Guidance: Revenue for fiscal year 2016 is expected to be in the range of $92 million to $93 million. Net loss is expected to be in the range of $6 million to $7 million. Net loss projections include approximately $6.4 million of expense related to the extinguishment of debt, as well as stock based compensation expense of approximately $3.6 million related to restricted stock grants and shares issued in connection with the initial public offering.  Adjusted EBITDA is expected to be in the range of $12.5 million to $13.0 million.

TRHC has not provided a reconciliation of projected GAAP Net Income to Adjusted EBITDA guidance because estimates of certain reconciling items cannot be provided without unreasonable effort. Our Adjusted EBITDA guidance for the year ending December 31, 2016, assumes anticipated losses of $6.4 million related to the extinguishment of debt, income of $0.6 million related to the remeasurement of our warrant liability, projected stock compensation of $4.2 million, projected depreciation and amortization charges of $5.1 million and interest expense of $4.5 million. In addition, we assume $0.4 million of income tax expense related to indefinite-lived deferred tax liabilities for goodwill amortization. We cannot provide a reliable forward-looking estimate of certain other reconciling items because they are either event-driven or difficult to quantify without unreasonable effort, in particular the revaluation of our contingent consideration.

Tabula Rasa HealthCare Chairman and CEO Calvin H. Knowlton, PhD to Receive Circle of Excellence – Technology Award from SmartCEO

MOORESTOWN, N.J., Nov. 01, 2016 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare(NASDAQ:TRHC) announced today its Chairman and CEO Calvin H. Knowlton, PhD, has been named a finalist by SmartCEO magazine for its 2016 Circle of Excellence – Technology Award. The Award “recognizes the region’s most accomplished CEOs for business excellence”.

According to SmartCEO, companies are nominated from all size and industry categories, public and private. An independent committee of business leaders selects the winners based on “industry impact, innovation and market leadership”.

“Tabula Rasa HealthCare is devoted to leveraging technology to improve health care,” said Knowlton. “We are at the forefront of precision medicine with solutions that help clients tailor medical treatment to the individual characteristics of each patient. Our cloud-based software applications are designed to identify high-risk individuals, detect susceptibility to adverse drug events (ADEs) and embed proper dosing guidelines.”

TRHC products and services are built around the Company’s proprietary Medication Risk Mitigation Matrix® and other software applications that provide solutions for a range of payors, providers and healthcare organizations.  TRHC is the market leader in providing medication risk management, risk adjustment and front-end coding for the Program of All-Inclusive Care for the Elderly (PACE), as well as a leader in pharmacy cost management solutions.

Finalists will be profiled in the November/December issue of SmartCEO magazine. The winners are celebrated at a gala event November 9, 2016 in Philadelphia.

About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.TRHC.com.

Contact:
Media
Dianne Semingson
dsemingson@TRHC.com
T: 215-870-0829

Investors
Bob East or Asher Dewhurst
Westwicke Partners
443-213-0500
tabularasa@westwicke.com

Tabula Rasa Healthcare to Announce Third Quarter 2016 Operating Results and Host Conference Call on Wednesday, November 9, 2016

MOORESTOWN, N.J., Oct. 26, 2016 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare, Inc.(NASDAQ:TRHC), a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk, will release its third quarter 2016 operating results on Wednesday, November 9, 2016 after market close, with a conference call to follow at 5:00 p.m. EDT.

Stockholders and interested participants may listen to a live broadcast of the conference call by dialing 844-413-0947 or 216-562-0423 for international callers, and referencing participant code 98688454 approximately 15 minutes prior to the call. A live webcast of the conference call will be available on the investor relations section of the company’s web site and an audio file of the call will also be archived for 90 days at ir.trhc.com. After the conference call, a replay will be available until December 9, 2016 and can be accessed by dialing 855-859-2056 or 404-537-3406 for international callers, and referencing participant code 98688454.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.tabularasahealthcare.com.

Contact:
 
Investors
Bob East or Asher Dewhurst
Westwicke Partners
443-213-0500
tabularasa@westwicke.com
 
Media
Dianne Semingson
dsemingson@TRHC.com
215-870-0829

Tabula Rasa Healthcare, Inc.

Tabula Rasa HealthCare Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

MOORESTOWN, N.J., Oct. 04, 2016 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare, Inc.(NASDAQ:TRHC), a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk, today announced the closing of its initial public offering of 4,945,000 shares of common stock at an initial public offering price of $12.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 645,000 additional shares of common stock. All of the shares in the offering were offered by Tabula Rasa. Tabula Rasa’s common stock is listed on the NASDAQ Global Marketunder the ticker symbol “TRHC.” Tabula Rasa estimates net proceeds from the offering to be approximately $51.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Wells Fargo Securities and UBS Investment Bank acted as joint-book running managers for the offering.  Piper Jaffray also acted as a book-runner and Baird and Stifel acted as co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on September 28, 2016. The offering will be made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to this offering, when available, may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov, or alternatively, from: Wells Fargo Securities, LLC by mailing: Attention: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, by email: cmclientsupport@wellsfargo.com or by Telephone: (800) 326-5897, or from UBS Securities LLC by mailing: Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019 or by Telephone: (888) 827-7275.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.tabularasahealthcare.com.

Contact
Bob East or Asher Dewhurst
Westwicke Partners
443-213-0500
tabularasa@westwicke.com

Tabula Rasa Healthcare, Inc.

Tabula Rasa HealthCare Announces Pricing of Initial Public Offering

MOORESTOWN, N.J., Sept. 28, 2016 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare, Inc.(NASDAQ:TRHC), a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk, today announced the pricing of its initial public offering of 4,300,000 shares of its common stock, at a price of $12.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Tabula Rasa.  The shares are expected to begin trading on The NASDAQ Global Market on September 29, 2016, under the symbol “TRHC.” In addition, Tabula Rasa granted the underwriters a 30-day option to purchase up to 645,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. This offering is expected to close on October 4, 2016, subject to customary closing conditions.

Wells Fargo Securities and UBS Investment Bank are acting as joint-book running managers for the offering.  Piper Jaffray is also acting as a book-runner, with Baird and Stifel acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on September 28, 2016. The offering will be made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to this offering, when available, may be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov, or alternatively, from: Wells Fargo Securities, LLC by mailing: Attention: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, by email: cmclientsupport@wellsfargo.com or by Telephone: (800) 326-5897, or from UBS Securities LLC by mailing: Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019 or by Telephone: (888) 827-7275.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contact
Bob East or Asher Dewhurst
Westwicke Partners
443-213-0500
tabularasa@westwicke.com

Tabula Rasa HealthCare CEO Named 2015 Health Care Innovator of the Year

Tabula Rasa Healthcare Chairman and CEO, Calvin H. Knowlton, BsPharm, M.Div., PhD., has been named “Individual Health Care Innovator of the Year” by the Philadelphia Business Journal. The Award will be presented October 22 at the Chrystal Tea Room in Philadelphia, PA.

The purpose of the award is “to recognize those companies, products and individuals that are leading the pack in bringing break-through innovation in healthcare and the life sciences to the greater Philadelphia community.”

Dr. Knowlton is the Co-founder, Chairman and CEO of Tabula Rasa HealthCare, Inc. (TRHC), a leader in providing patient-specific, data-driven technology and solutions that enable health care organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower health care costs and manage risk.

“We believe we are at the forefront of precision medicine with solutions that help our clients tailor medical treatment to the individual characteristics of each patient. Health care organizations are starting to recognize the need for personalization to reduce trial and error prescribing, improve outcomes such as reducing hospitalizations and ER visits to a ‘new normal,’ lessening utilization, and reducing total costs,” said Dr. Knowlton.

Dr. Knowlton has won numerous awards for his leadership in pharmacy, business, and philanthropy in his career spanning over 30 years, including the 2003 and the 2013 Ernst and Young Entrepreneur of the Year Award, Greater Philadelphia Region, and the 2004 Walter M. Aikman Entrepreneur of the Year Award. He was selected as the Most Influential U.S. Pharmacist in 1997. Most recently, Dr. Knowlton was recognized by the American Pharmacist Association with the 2015 Remington Honor Medal for distinguished service on behalf of American pharmacy.

Dr. Knowlton has been elected and served as the President for the American College of Apothecaries, President of the American Pharmacists Association (APhA) and President of the American Pharmacists Association Foundation. He currently serves on the Board and Executive Committee of the Coriell Institute for Medical Research and chairs the Board of Coriell Life Sciences, Inc. He serves on the Board of the Cooper Medical School of Rowan University and the Board (Session) of the First Presbyterian Church in Moorestown NJ. He is a former member of Board of St. Christopher’s Hospital for Children in Philadelphia. Currently, Dr. Knowlton is a member of the APhA Pharmacogenomics Task Force, as well as the FDA recognized, National Pharmacogenomics Advisory Group.

Dr. Knowlton received his pharmacy degree from Temple University, his Divinity degree from Princeton Theological Seminary, and his PhD in pharmacoeconomics from the University of Maryland. He served as Professor and Department Chair for the University of the Sciences in Philadelphia in the 1990s. He has authored and co-authored text books, book chapters, and articles focused on the role and responsibility of pharmacists in the outcomes of patient-centered medication care.

About Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s leading offering, and its cloud-based software applications, including EireneRx and MedWise Advisor, provide solutions for a range of payers, providers and other healthcare organizations.

Read more about Geeks by www.forwardgeek.com

 

Page 1 of 212»